Emergent Biosolutions Inc. (NYSE:EBS) saw unusually-high trading volume on Wednesday . Approximately 823,569 shares traded hands during mid-day trading, an increase of 64% from the previous session’s volume of 500,893 shares.The stock last traded at $28.59 and had previously closed at $28.00.

EBS has been the subject of several research reports. Cowen and Company downgraded Emergent Biosolutions from an “outperform” rating to a “market perform” rating in a report on Wednesday, June 22nd. JPMorgan Chase & Co. reduced their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a research note on Friday, August 5th. Singular Research reduced their price objective on Emergent Biosolutions from $44.00 to $40.00 and set a “buy” rating for the company in a research note on Tuesday, June 28th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Wednesday, June 22nd. Finally, Zacks Investment Research downgraded Emergent Biosolutions from a “hold” rating to a “sell” rating in a research note on Tuesday, June 28th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Emergent Biosolutions presently has a consensus rating of “Buy” and a consensus target price of $40.00.

The firm has a market cap of $1.16 billion, a P/E ratio of 20.45 and a beta of 1.24. The stock has a 50-day moving average of $27.72 and a 200-day moving average of $34.37.

Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. The business had revenue of $101.49 million for the quarter, compared to analyst estimates of $111.20 million. Emergent Biosolutions had a net margin of 11.61% and a return on equity of 11.93%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.36 earnings per share. On average, equities analysts forecast that Emergent Biosolutions Inc. will post $1.03 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. Raymond James & Associates increased its stake in shares of Emergent Biosolutions by 0.4% in the second quarter. Raymond James & Associates now owns 8,456 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 36 shares in the last quarter. New York State Teachers Retirement System increased its stake in shares of Emergent Biosolutions by 0.3% in the second quarter. New York State Teachers Retirement System now owns 36,755 shares of the biopharmaceutical company’s stock valued at $1,034,000 after buying an additional 100 shares in the last quarter. Hancock Holding Co. increased its stake in shares of Emergent Biosolutions by 0.5% in the second quarter. Hancock Holding Co. now owns 24,130 shares of the biopharmaceutical company’s stock valued at $679,000 after buying an additional 130 shares in the last quarter. Howe & Rusling Inc. increased its stake in shares of Emergent Biosolutions by 3.0% in the second quarter. Howe & Rusling Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $137,000 after buying an additional 140 shares in the last quarter. Finally, Louisiana State Employees Retirement System increased its stake in shares of Emergent Biosolutions by 1.5% in the second quarter. Louisiana State Employees Retirement System now owns 13,800 shares of the biopharmaceutical company’s stock valued at $388,000 after buying an additional 200 shares in the last quarter. Institutional investors own 89.95% of the company’s stock.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

5 Day Chart for NYSE:EBS

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.